BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $6.86, for a total value of $54,880.00. Following the sale, the director now owns 564,754 shares in the company, valued at approximately $3,874,212.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
BDSI stock traded up $0.04 during trading on Friday, hitting $6.53. The company had a trading volume of 11,255 shares, compared to its average volume of 975,548. The firm has a market cap of $605.16 million, a PE ratio of -8.93 and a beta of 0.49. BioDelivery Sciences International, Inc. has a 1-year low of $2.80 and a 1-year high of $7.01. The firm has a 50-day moving average price of $5.97 and a 200-day moving average price of $4.76. The company has a quick ratio of 2.02, a current ratio of 2.25 and a debt-to-equity ratio of 0.86.
BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Tuesday, November 12th. The specialty pharmaceutical company reported $0.33 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.34. The firm had revenue of $30.31 million for the quarter, compared to analysts’ expectations of $28.86 million. BioDelivery Sciences International had a negative return on equity of 8.80% and a negative net margin of 22.11%. Sell-side analysts anticipate that BioDelivery Sciences International, Inc. will post 0.02 earnings per share for the current year.
A number of analysts have recently commented on BDSI shares. William Blair reiterated a “buy” rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 17th. ValuEngine upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Tuesday. BidaskClub cut BioDelivery Sciences International from a “strong-buy” rating to a “buy” rating in a research report on Friday. TheStreet upgraded BioDelivery Sciences International from a “d” rating to a “c” rating in a research report on Friday, November 22nd. Finally, LADENBURG THALM/SH SH lifted their target price on BioDelivery Sciences International from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $6.50.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Featured Article: What is diluted earnings per share (Diluted EPS)?
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.